



NEWS RELEASE

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentive Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

2026-09-17

- Built Inside Active Clinical Programs: A New Generation of AI Co-Scientists Designed to Compress Research Timelines and Expand What Is Possible in Drug Development
- Open-Medicine AI Founder & CEO Panna Sharma to Detail How Open-Medicine AI Is Evolving Beyond Rare Cancers to Target Additional Disease Categories, New Modalities, and Critical Downstream Real-World Drug Development Challenges
- Webinar to Be Held Wednesday, September 23, 2026 at 12:30 PM Eastern / 9:30 AM Pacific — **Register Here**

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company's wholly owned subsidiary building a multi-agentive AI platform for end-to-end therapeutic development.

Panna Sharma, Founder and CEO of Open-Medicine AI, will lead the session, which is intended for investors, biopharma and academic collaborators, and prospective partners. The webinar will explain how OMAI is extending the AI co-scientist approach first commercialized in withZeta.ai — launched in April 2026 and focused on rare and

aggressive cancers — into additional disease categories, new therapeutic modalities, and the downstream development challenges that consume most of the time and cost between a validated target and a treated patient. A question-and-answer period will follow the presentation.

Built Where the Problems Are

Most AI for drug discovery is built at a distance from drug development. Open-Medicine AI was built inside it. Its co-scientists were developed within Lantern's own clinical programs — with the same data, constraints, regulatory requirements, and decision points that determine whether a molecule reaches patients — and were first put to work in withZeta.ai, which launched in April 2026 and is in use across rare and aggressive cancers.

The drug discovery and development markets are already moving in this direction. Independent analysts estimate the AI in drug discovery market at approximately \$2.9 billion in 2026, growing to \$13.8 billion by 2033.¹ Additionally, analysts have noted that AI deployments in pharma are moving from pilots to enterprise-scale, agentic systems.^{2, 3}

The result is a platform that does more than propose candidates. It reasons across the full development pathway — target and biomarker selection, compound and modality design, translational analysis, trial design, and regulatory strategy — in which the agents carry the operating knowledge of the scientists and clinicians who built them. The webinar will present:

- The platform: the multi-agentic architecture behind Open-Medicine AI, how its co-scientists coordinate across the development pathway, and what distinguishes an agent trained inside active clinical programs from a general-purpose model
- The roadmap: the next generation of co-scientists beyond rare cancers, the disease categories and therapeutic modalities being prioritized, and the downstream development challenges — trial design, patient selection, regulatory and translational work — that the platform is being extended to address
- The business model: how Open-Medicine AI intends to generate revenue through subscription access and enterprise licensing, and how it works with biopharma companies, research institutions, service providers, and drug developers
- The value proposition: where the platform is designed to remove time, cost, and failure from the path between a validated target and a treated patient, and how that is measured
- Why now: why an AI platform for therapeutic development is best built by a company that develops therapeutics, and what that means for Lantern Pharma shareholders and for the researchers, developers, and technology partners who will use it

"We did not set out to build an AI company. We set out to get cancer drugs to patients faster and with less capital, and we built the tools we needed to do that because they did not exist. withZeta.ai is what came out of that work,

and it is now running inside real programs with real regulatory and clinical consequences. Open-Medicine AI takes that architecture beyond rare cancers and beyond Lantern — into new disease categories, new modalities, and the downstream parts of development where most of the time, cost, and failure live. On September 23 we will show what we have built, how it will be adopted by industry professionals and service providers, and what the development roadmap for the platform and business could look like. We believe that the most useful AI for therapeutic development will come from the people who have actually developed therapeutics and taken them into meaningful trials for the benefit of patients, and done so with a data-driven, time- and cost-conscious mentality.”

— Panna Sharma, President and Chief Executive Officer, Lantern Pharma

Webinar Details

Title	Open-Medicine AI: A Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition
Date	Wednesday, September 23, 2026
Time	12:30 PM Eastern / 9:30 AM Pacific
Presenter	Panna Sharma, President and CEO, Lantern Pharma; Founder and CEO, Open-Medicine AI
Format	45 minutes — a 30–35 minute presentation followed by live Q&A; questions may be submitted in advance to IR@lanternpharma.com
Registration	https://us06web.zoom.us/webinar/register/9417895172347/WN_HNjzsDuTjufesN-cdwaNw#/registration
Replay	A recording will be available on the Investors section of www.lanternpharma.com following the event

About Open-Medicine AI

Open-Medicine AI (OMAI) is a wholly owned subsidiary of Lantern Pharma building a multi-agentic AI platform for end-to-end therapeutic development. Its AI co-scientists were developed inside Lantern’s clinical-stage oncology programs and carry the data, constraints, and decision points of real drug development — from target and biomarker selection through compound design, translational analysis, trial design, and regulatory strategy. The platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers, and expanded in July 2026 with ZetaOmics™, a computational biology module released to early-access users. OMAI is extending this architecture to additional disease categories, new therapeutic modalities, and the downstream challenges of drug development. The platform is available to biopharma companies, research institutions, service providers, and drug developers through subscription and enterprise licensing. For more information, visit www.open-medicine.ai.

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug

development. By integrating large-scale genomic and biological data with advanced machine learning, RADR® is designed to identify the patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For more information, visit www.lanternpharma.com.

Selected References

1. Grand View Research. Artificial Intelligence in Drug Discovery Market Size, Share & Trends Analysis Report, 2026–2033. Available at: grandviewresearch.com.
2. IntuitionLabs. Big Pharma & Hyperscaler AI Deals: 2026 Industry Tracker. 2026. Available at: intuitionlabs.ai.
3. Securities.io - AI Drug Discovery Is Triggering a Biotech M&A Supercycle – Available at <https://www.securities.io/ai-drug-discovery-biotech-ma-supercycle-2026/>

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the market opportunity, platform roadmap, and commercial model for the Open-Medicine AI platform; the planned evolution of the Open-Medicine AI platform beyond withZeta.ai to target broader disease areas, new modalities, and additional real-world drug development challenges; the planned development, value proposition and commercial potential of the Open-Medicine AI platform, including our plans to compress research timelines and expand what is possible in drug development; and the potential advantages of the Open Medicine AI platform in identifying drug candidates, accelerating drug development, and generating revenue through software licensing and subscription models.

Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned development programs and operations, (ii) the risk that our Open-Medicine AI commercialization efforts may not generate the anticipated revenue or

achieve the expected market adoption, (iii) the risk that implementation of our development plans and new features for Open-Medicine AI may not be successful or may take longer than anticipated for development, completion, and release, (iv) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) technical, scientific, regulatory, financial, competitive, and operational risks and those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.

You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

Media & Investor Contacts

Lantern Pharma — Investor Relations

Email: IR@lanternpharma.com

Phone: (972) 277-1136

Source: Lantern Pharma Inc.